

Applicant : David J. Pinsky et al.,
Serial No.: 09/671,100
Filed : September 27, 2000
Page 3

NNN is the complement to a DNA codon for any one of the standard amino acids other than aspartic acid and cysteine.

3) Oligonucleotides for producing Factor IXmi (His221-NNN)

3'-TTA CAT TGA CGA CGG NNN ACA CAA CTT TGA CCA-5' (SEQ ID NO:19)

where

W is A, 3'-AA, or 3'-TAA

V is C, 3'-CC, or 3'-CCA

NNN is the complement to DNA codon for any one of the standard amino acids other than histidine and cysteine.

Oligonucleotide primers for producing the preferred Factor IXmi of this invention, Factor IXmi(Ser365→Ala), are those of No. 1 above, wherein NNN is the complement of a codon for alanine, i.e., 3' CGA, 3'-CGC, 3'-CGT or 3'CGC. A specific primer for producing Factor IXmi(Ser365→Ala) is:

3'-GT ACA GTT CCT CTA **CGA** CCC CCT GGG GTA C-5' (SEQ ID NO: 20)

REMARKS

The Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures states that the above-identified application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c). In addition, the notice states that a copy of the "Sequence Listing" in computer readable has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R.

Applicant : David J. Pinsky et al.
Serial No.: 09/671,100
Filed : September 27, 2000
Page 4

1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."

The Notice states that applicant must provide: 1)an initial or substitute computer readable form (CRF) copy of the "Sequence Listing"; 2)an initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification; and 3)a statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. §1.821(e) or §1.821(f) or §1.821(g) or §1.825(b) or §1.825(d).

In response, applicants respectfully traverse the Examiner's above objection. Nevertheless, applicants without conceding the correctness of the Examiner's position but to expedite prosecution of the subject application enclose a computer diskette containing the sequence listing in computer readable form. Applicants attach hereto, as **Exhibit C** a paper copy of the revised computer readable form of the sequence listing. Applicants attach hereto as **Exhibit D** a Statement in Compliance with 37 C.F.R. §1.821(f) certifying that the computer readable form contains the same information as the paper copy of the sequence listing attached as **Exhibit C**. The sequence listing does not contain any new matter.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invite the Examiner to telephone him at the number provided below.

Applicant : David J. Pinsky et al.
Serial No.: 09/671,100
Filed : September 27, 2000
Page 5

No fee, other than the enclosed \$985.00 fee for a five-month extension of time, is deemed necessary in connection with the filing of this Amendment. However, if an additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White
Registration No. 28,678
Attorney for Applicant(s)
Cooper & Dunham, LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington VA 22202

 1/29/03
John P. White
Reg. No. 28,678

Date




EXHIBIT B: MARKED-UP VERSION OF SPECIFICATION

Please delete the paragraphs on page 25, lines 22-38 through page 26, lines 1-16 and replace them with the following paragraphs:

1) Oligonucleotides for producing Factor IXmi (Ser365→[XXX]
NNN)

3'-W ACA GTT CCT CTA [XXX] NNN CCC CCT GGG GTA V-5' (SEQ ID NOS:1-9)

where

W is T, 3'-GT or 3'-AGT

V is C, 3'-CA, or 3'-CAA

[XXX] NNN is the complement to a DNA codon for any one of the standard amino acids other than serine.

2) Oligonucleotides for producing [FACTOR] Factor IXmi
(Asp269→[Yyy] NNN)

3'-W TTC ATG TTA GTA [Yyy] NNN TAA CGC GAA GAC V-5' (SEQ ID NOS:10-18)

where

W IS A, 3' [=] -TA, OR 3'-TTA

V is C, 3'-CT, or 3'-CTT

[Yyy] NNN is the complement to a DNA codon for any one of the standard amino acids other than aspartic acid and cysteine.

3) Oligonucleotides for producing Factor IXmi (His221→[Zzz] NNN)

3'-TTA CAT TGA CGA CGG [Zzz] NNN ACA CAA CTT TGA CCA-5' (SEQ ID NO:19)

where

W is A, 3'-AA, or 3'-TAA

V is C, 3'-CC, or 3'-CCA

[Zzz] NNN is the complement to DNA codon for any one of the standard amino acids other than histidine and cysteine.

Oligonucleotide primers for producing the preferred Factor IXmi of this invention, Factor IXmi(Ser365-Ala), are those of No. 1 above, wherein [XXX] NNN is the complement of a codon for alanine, i.e., 3' CGA, 3'-CGC, 3'-CGT or 3'CGC. A specific primer for producing Factor IXmi(Ser365-Ala) is:

3'-GT ACA GTT CCT CTA **CGA** CCC CCT GGG GTA C-5' (SEQ ID NO: 20)